Skip to content

Released Aug 8, 2022, after the close

10-Q filed Aug 9, 2022, 40 days after period end · 0001162194-22-000091

Q2 2022 · 10-Q
Revenue$18.78M−39.5% vs Q2 2021−29.2% vs Q1 2022
Net Income-$63.54MN/M vs Q2 2021N/M vs Q1 2022
EPS Diluted-$0.82N/M vs Q2 2021N/M vs Q1 2022
Gross Profit$4,427,000—
Operating Income-$38,563,000N/M
Operating Cash Flowderived-$29,988,000N/M
Free Cash Flowderived-$30,926,000N/M
Margins · derived
Gross margin23.6%
Operating margin-205.4%−149.7 pt vs Q2 2021
Net margin-338.4%−283.1 pt vs Q2 2021

What the release said

The release

Same quarter

MetricQ2 2022Q2 2021Q2 2020Q2 2019
Revenue$18.78M$31.02M$26.06M$28.20M
Net Income-$63.54M-$17.14M-$13.02M-$13.75M
EPS Diluted-$0.82-$0.23-$0.18-$0.20

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR